Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €12.40 EUR
Change Today +0.015 / 0.12%
Volume 7.6K
KDS On Other Exchanges
EN Amsterdam
As of 7:37 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

kiadis pharma nv (KDS) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/2/15 - €12.85
52 Week Low
07/9/15 - €11.36
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KIADIS PHARMA NV (KDS)

Related News

No related news articles were found.

kiadis pharma nv (KDS) Related Businessweek News

No Related Businessweek News Found

kiadis pharma nv (KDS) Details

Kiadis Pharma N.V. researches, develops, and commercializes cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Its products provide for Allodepleted T-cell ImmunotheRapeutics (ATIR). The company offers ATIR101 that addresses the risks and limitations of current hematopoietic stem cell transplantation treatments in blood cancers. The company also develops ATIR201 for inherited blood disorders with an initial focus on thalassemia. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam-Duivendrecht, the Netherlands.

23 Employees
Last Reported Date: 06/17/15
Founded in 1997

kiadis pharma nv (KDS) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: €365.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €170.9K
Compensation as of Fiscal Year 2014.

kiadis pharma nv (KDS) Key Developments

Kiadis Pharma N.V. Auditor Raises 'Going Concern' Doubt

Kiadis Pharma N.V. filed its Annual on Jun 17, 2015 for the period ending Dec 31, 2014. In this report its auditor, KPMG LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Kiadis Pharma Seeks Acqusiitions

Kiadis Pharma B.V. will use the proceeds of the IPO in the amount of €35.94million to finance potential opportunities to broaden and diversify the research and development portfolio (e.g. through in-licensing or the acquisition of programs and companies with synergistic or complementary technologies, products and/or product candidates.)

Kiadis Pharma To File IPO

Kiadis Pharma B.V. is planning to raise funds for research through the listing of its shares on the Amsterdam and Brussels stock exchanges. It intends to use the net proceeds to support further clinical development of ATIR101 and ATIR201, production process optimization and automation, diversify the R&D portfolio, and remaining proceeds for working capital and general corporate purposes.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KDS:NA €12.40 EUR +0.015

KDS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KDS.
View Industry Companies

Industry Analysis


Industry Average

Valuation KDS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KIADIS PHARMA NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at